Original ResearchFull Report: Clinical—Alimentary TractGlutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients With Celiac Disease
Section snippets
Gluten-Dose Optimization
To determine the optimal dose of gluten to be used in the interventional study, gluten challenges with 1.5 g, 3.0 g, or 6.0 g gluten (using breadcrumbs) were administered daily to adult celiac disease patients for 6 weeks (see Supplementary Material for gluten content assessment). Eligibility criteria included celiac disease diagnosis established by duodenal mucosal biopsy, attempted adherence to a GFD for 1 year or more, and being in clinical remission (ie, TG2-IgA−negative and reporting
Gluten-Dose Optimization
Before conducting the therapeutic intervention study, the optimal gluten-challenge dose was identified. Forty-seven patients were enrolled (Table 1) and assigned to 1 of 3 groups receiving a gluten challenge of 6.0 g (n = 17), 3.0 g (n = 15), or 1.5 g (n = 15) daily divided in 3 doses. The baseline mean VH:CrD values were similar in each group: 2.8, 2.6, and 2.8, respectively. All patients in the 6 g gluten/day group completed the study; 2 patients in the 3.0 g/day and 1 in the 1.5 g/day gluten
Discussion
Many celiac disease patients desire a novel nondietary alternative to the strict life-long GFD.14, 15, 35, 36 Despite long-term dietary gluten exclusion, small intestinal mucosal injury with crypt hyperplasia (Marsh grade II−III) is still present in 20%−80% of patients.12 In Finland, despite villus recovery in response to the GFD (96% with Marsh grade 0−I), persistent intraepithelial lymphocytosis is seen in more than half of patients studied.12 Small bowel mucosal healing is a prerequisite for
Acknowledgments
The authors are grateful to Robert N. Williams for the assistance with graphics design and statistical support.
Clinicaltrial.gov, ID: NCT00959114 and NCT01255696.
References (49)
- et al.
The American Gastroenterological Association (AGA) Institute technical review on the diagnosis and management of celiac disease
Gastroenterology
(2006) - et al.
Celiac disease: from pathogenesis to novel therapies
Gastroenterology
(2009) - et al.
Duodenal histology in patients with celiac disease after treatment with a gluten-free diet
Gastrointest Endosc
(2003) - et al.
Rational design of combination enzyme therapy for celiac sprue
Chem Biol
(2006) - et al.
The effects of ALV003predigestion of gluten on immune response and symptoms in celiac disease in vivo
Clin Immunol
(2010) - et al.
Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue
Gastroenterology
(2007) - et al.
Intraepithelial gamma/delta T-cell-receptor lymphocytes and genetic susceptibility to coeliac disease
Lancet
(1992) - et al.
Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease
Gastroenterology
(1998) - et al.
Morphology of the mucosal lesion in gluten sensitivity
Baillieres Clin Gastroenterol
(1995) - et al.
Comparison of the interobserver reproducibility with different histologic criteria used in celiac disease
Clin Gastroenterol Hepatol
(2007)
Diagnosis of lactose intolerance and the “nocebo” effect: the role of negative expectations
Dig Liver Dis
Wheat
J Bot
Postpubertal gluten challenge in coeliac disease
Arch Dis Child
The daily gluten intake in relatives of patients with coeliac disease compared with that of general Dutch population
Eur J Gastroenterol Hepatol
Intestinal digestive resistant immunodominant gliadin peptides
Am J Physiol Gastrointest Liver Physiol
Structural basis for gluten intolerance in celiac sprue
Science
Effect of prolyl endopeptidase on digestive resistant gliadin peptides in vivo
Pharmacol Exp Ther
High rate of gastrointestinal symptoms in celiac disease patients living on a gluten-free diet: controlled study
Am J Gastroenterol
Coeliac disease: a histological follow-up study
Histopathology
Persistent duodenal intraepithelial lymphocytosis despite a long-term strict gluten-free diet in celiac disease
Am J Gastroenterol
Systematic review: adherence to a gluten-free diet in adult patients with coeliac disease
Aliment Pharmacol Ther
Novel therapies for celiac disease
J Intern Med
Recent advances in the development of new treatments for celiac disease
Expert Opin Biol Ther
Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials
Dig Dis Sci
Cited by (190)
Further Progress to Quantify Histological Damage in Patients With Celiac Disease
2024, Clinical Gastroenterology and HepatologyCeliac disease: mechanisms and emerging therapeutics
2023, Trends in Pharmacological SciencesA Composite Morphometric Duodenal Biopsy Mucosal Scale for Celiac Disease Encompassing Both Morphology and Inflammation
2023, Clinical Gastroenterology and HepatologyLatiglutenase Protects the Mucosa and Attenuates Symptom Severity in Patients With Celiac Disease Exposed to a Gluten Challenge
2022, GastroenterologyCitation Excerpt :IMGX003, upon dissolution in 6–8 ounces of water, provides a fixed-dose combination glutenase consisting of a 1:1 ratio by weight of the 2 gluten targeting enzymes, which demonstrate complementary substrate sequence and chain length specificity. The properties of IMGX003 have been described previously9–12 and are briefly presented, along with a description of the gluten samples, in the Supplementary Material. Masked study medication (MSM) (IMGX003 or placebo) and gluten were orally administered.
Quantitative histology as a diagnostic tool for celiac disease in children and adolescents
2022, Annals of Diagnostic PathologyCeliac disease: New therapies on the horizon
2022, Current Opinion in Pharmacology
Conflicts of interest These authors disclose the following: Marja-Leena Lähdeaho is the principal investigator and is employed by FinnMedi Oy. Tiina Kärjä-Lahdensuu is an employee of FinnMedi Oy. Annette Marcantonio and Daniel C. Adelman are employees of Alvine Pharmaceuticals, Inc. Markku Mäki is a scientific advisor to Alvine Pharmaceuticals, Inc., ImmusanT, Inc, BioLineRx, Ltd, and Flamentera, AG. The remaining authors disclose no conflicts.
Funding This study was sponsored by Alvine Pharmaceuticals, Inc., San Carlos, CA. Celiac Disease Study Group (M.-L.L., K.K., K.L., and M.M.) received financial supported by the Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital (Grants 9R034 and 9R018), Academy of Finland, and The Sigrid Juselius Foundation.